CAJ | 학술논문

目的：探讨血脂康在降低血脂正常脑梗死患者不良心脑血管事件中的效果。方法将2010年1-12月300例血脂正常的脑梗死患者随机分为A组(常规干预组)、B组(阿托伐他汀组)和C组(血脂康组)各100例，比较三组患者不良心脑血管事件发生率、不良反应发生率及干预前后的颈动脉内膜中层厚度、血清CK、CK-MB及AST、ALT。结果 B组与C组的不良心脑血管事件发生率均低于A组，干预后的血清CK、CK-MB低于A组，颈动脉内膜中层厚度优于A组，且C组不良反应发生率低于B组，P均<0.05，均有显著差异，而三组干预前后的血清AST与ALT均无显著性差异，P均>0.05。结论血脂康在降低血脂正常脑梗死患者不良心脑血管事件中的效果较好，可有效降低血管风险程度。
목적：탐토혈지강재강저혈지정상뇌경사환자불양심뇌혈관사건중적효과。방법장2010년1-12월300례혈지정상적뇌경사환자수궤분위A조(상규간예조)、B조(아탁벌타정조)화C조(혈지강조)각100례，비교삼조환자불양심뇌혈관사건발생솔、불량반응발생솔급간예전후적경동맥내막중층후도、혈청CK、CK-MB급AST、ALT。결과 B조여C조적불양심뇌혈관사건발생솔균저우A조，간예후적혈청CK、CK-MB저우A조，경동맥내막중층후도우우A조，차C조불량반응발생솔저우B조，P균<0.05，균유현저차이，이삼조간예전후적혈청AST여ALT균무현저성차이，P균>0.05。결론혈지강재강저혈지정상뇌경사환자불양심뇌혈관사건중적효과교호，가유효강저혈관풍험정도。
Objective To study the effect of Xuezhikang in decreasing the adverse cardiovascular and cerebrovascular events of patients with normal blood lipid and cerebral infarction. Methods 300 patients with normal blood lipid and cerebral infarction from January 2010 to December 2010 were selected as research object,and they were randomly divided into group A(routine treatment group) 100 cases,group B(atorvastatin group) 100 cases and group C(Xuezhikang group) 100 cases, then the adverse cardiovascular and cerebrovascular events rate, adverse reaction rate and carotid artery intima-media thickness, serum CK, CK-MB, AST, ALT before and after the intervention of two groups were compared. Results The adverse cardiovascular and cerebrovascular events rate of group B and group C were both lower than that of group A, serum CK and CK-MB after the intervention were lower than those of group A, carotid artery intima-media thickness were better than those of group A, and adverse reaction rate of group C was lower than that of group B, all P<0.05, there were all significant differences, while the serum AST and ALT of three groups had no significant differences, all P>0.05. Conclusion The effect of Xuezhikang in decreasing the adverse cardiovascular and cerebrovascular events of patients with normal blood lipid and cerebral infarction is better, and it can effectively decrease the vascular risk degree.